Hutchinson Gilford Progeria Syndrome

Sorry, no news articles match your request. Your search criteria may be too narrow.

Progeria (also known as "Hutchinson–Gilford Progeria Syndrome", "Hutchinson–Gilford syndrome", and "Progeria syndrome") is an extremely rare genetic condition wherein symptoms resembling aspects of aging are manifested at an early age. The word progeria comes from the Greek words "pro" (πρό), meaning "before", and "géras" (γῆρας), meaning "old age". The disorder has very low incidences and occurs in an estimated 1 per 8 million live births. Those born with progeria typically live to their mid teens and early twenties. It is a genetic condition that occurs as a new mutation (de novo), and is rarely inherited. Although the term progeria applies strictly speaking to all diseases characterized by premature aging symptoms, and is often used as such, it is often applied specifically in reference to Hutchinson-Gilford Progeria Syndrome(HGPS).

Scientists are particularly interested in progeria because it might reveal clues about the normal process of aging. Progeria was first described in 1886 by Jonathan Hutchinson. It was also described independently in 1897 by Hastings Gilford. The condition was later named Hutchinson-Gilford Progeria Syndrome (HGPS).

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Echolocation acts as substitute sense for blind people

Recent research carried out by scientists at Heriot-Watt University has demonstrated that human echolocation operates as a viable 'sense', working in tandem with other senses to deliver information to people with visual impairment.

Vitamin D link to short-sightedness ruled out

New findings from the Children of the 90s study at the University of Bristol suggest that children with low levels of vitamin D in their blood are not at increased risk of developing myopia (short-sightedness).

Bone loss drugs may help prevent endometrial cancer

A new analysis suggests that women who use bisphosphonates—medications commonly used to treat osteoporosis and other bone conditions—have about half the risk of developing endometrial cancer as women who do not use the ...